Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 29 | 2024 | 507 | 8.210 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 21 | 2024 | 218 | 7.270 |
Why?
|
Biomarkers, Tumor | 12 | 2024 | 179 | 4.290 |
Why?
|
Autoantibodies | 5 | 2021 | 71 | 1.960 |
Why?
|
Multiple Pulmonary Nodules | 3 | 2022 | 11 | 1.850 |
Why?
|
Insulin-Like Growth Factor I | 6 | 2024 | 52 | 1.440 |
Why?
|
Biomarkers | 9 | 2024 | 556 | 1.300 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 186 | 1.160 |
Why?
|
Immunoassay | 3 | 2018 | 37 | 1.120 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 9 | 0.990 |
Why?
|
Body Composition | 2 | 2024 | 62 | 0.960 |
Why?
|
Solitary Pulmonary Nodule | 2 | 2015 | 13 | 0.920 |
Why?
|
Prognosis | 10 | 2024 | 758 | 0.920 |
Why?
|
Adenocarcinoma | 5 | 2018 | 123 | 0.910 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 62 | 0.900 |
Why?
|
Humans | 48 | 2024 | 26286 | 0.900 |
Why?
|
Neoplasm Staging | 7 | 2024 | 314 | 0.830 |
Why?
|
Middle Aged | 21 | 2024 | 8601 | 0.820 |
Why?
|
Immunotherapy | 2 | 2024 | 48 | 0.780 |
Why?
|
Early Detection of Cancer | 5 | 2022 | 85 | 0.780 |
Why?
|
Aged | 21 | 2024 | 8765 | 0.760 |
Why?
|
Cachexia | 2 | 2019 | 13 | 0.730 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2021 | 15 | 0.730 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 37 | 0.720 |
Why?
|
Aged, 80 and over | 13 | 2024 | 4675 | 0.720 |
Why?
|
Female | 25 | 2024 | 14539 | 0.690 |
Why?
|
Male | 24 | 2024 | 14162 | 0.680 |
Why?
|
HLA Antigens | 2 | 2021 | 15 | 0.660 |
Why?
|
Erlotinib Hydrochloride | 2 | 2020 | 10 | 0.650 |
Why?
|
Algorithms | 7 | 2022 | 366 | 0.650 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2018 | 6 | 0.610 |
Why?
|
Syndecan-1 | 1 | 2018 | 4 | 0.610 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2018 | 17 | 0.610 |
Why?
|
Vimentin | 2 | 2016 | 2 | 0.600 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 33 | 0.600 |
Why?
|
Nerve Growth Factors | 1 | 2018 | 35 | 0.590 |
Why?
|
Inflammation Mediators | 1 | 2018 | 58 | 0.580 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 34 | 0.550 |
Why?
|
Tandem Mass Spectrometry | 2 | 2013 | 21 | 0.540 |
Why?
|
Lymphatic Metastasis | 3 | 2012 | 80 | 0.530 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 224 | 0.530 |
Why?
|
Kidney Transplantation | 2 | 2016 | 120 | 0.530 |
Why?
|
Cytokines | 2 | 2014 | 226 | 0.480 |
Why?
|
Graft Rejection | 2 | 2016 | 63 | 0.480 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2014 | 8 | 0.480 |
Why?
|
Adult | 12 | 2018 | 7448 | 0.480 |
Why?
|
Predictive Value of Tests | 5 | 2014 | 460 | 0.470 |
Why?
|
Cohort Studies | 7 | 2024 | 1838 | 0.450 |
Why?
|
Doxazosin | 1 | 2013 | 1 | 0.450 |
Why?
|
Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 1 | 0.450 |
Why?
|
Chloroquine | 1 | 2013 | 7 | 0.450 |
Why?
|
Melanins | 1 | 2013 | 7 | 0.450 |
Why?
|
Immunoglobulin G | 3 | 2022 | 87 | 0.440 |
Why?
|
Sulfonamides | 1 | 2013 | 42 | 0.440 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 9 | 0.430 |
Why?
|
Multivariate Analysis | 4 | 2017 | 305 | 0.420 |
Why?
|
Immunoglobulin M | 2 | 2022 | 14 | 0.410 |
Why?
|
C-Peptide | 1 | 2011 | 6 | 0.390 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 485 | 0.390 |
Why?
|
Retrospective Studies | 7 | 2019 | 3367 | 0.380 |
Why?
|
Cell Line, Tumor | 7 | 2020 | 234 | 0.380 |
Why?
|
Blood Chemical Analysis | 1 | 2010 | 13 | 0.360 |
Why?
|
Survival Analysis | 3 | 2021 | 235 | 0.360 |
Why?
|
Hematologic Tests | 1 | 2010 | 6 | 0.360 |
Why?
|
Protein Array Analysis | 1 | 2010 | 10 | 0.360 |
Why?
|
Protein Kinase Inhibitors | 3 | 2020 | 45 | 0.350 |
Why?
|
ErbB Receptors | 4 | 2020 | 51 | 0.340 |
Why?
|
Area Under Curve | 4 | 2014 | 57 | 0.330 |
Why?
|
Lymph Nodes | 1 | 2009 | 62 | 0.310 |
Why?
|
Disease-Free Survival | 3 | 2017 | 159 | 0.310 |
Why?
|
Treatment Outcome | 6 | 2024 | 3391 | 0.300 |
Why?
|
Risk Assessment | 4 | 2017 | 629 | 0.290 |
Why?
|
Body Weight | 3 | 2024 | 121 | 0.290 |
Why?
|
Antigens, Neoplasm | 2 | 2021 | 38 | 0.270 |
Why?
|
Diagnosis, Differential | 2 | 2018 | 347 | 0.250 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 125 | 0.250 |
Why?
|
Antibodies, Viral | 2 | 2022 | 53 | 0.250 |
Why?
|
Animals | 11 | 2020 | 3538 | 0.250 |
Why?
|
Proteomics | 2 | 2018 | 90 | 0.230 |
Why?
|
Young Adult | 4 | 2018 | 1886 | 0.220 |
Why?
|
ROC Curve | 2 | 2014 | 137 | 0.220 |
Why?
|
Chondrocytes | 3 | 2014 | 148 | 0.220 |
Why?
|
Pneumonectomy | 2 | 2017 | 67 | 0.220 |
Why?
|
Reproducibility of Results | 3 | 2014 | 679 | 0.220 |
Why?
|
Prospective Studies | 3 | 2024 | 1668 | 0.210 |
Why?
|
Survival Rate | 2 | 2018 | 322 | 0.210 |
Why?
|
Mutation | 3 | 2020 | 315 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2016 | 171 | 0.210 |
Why?
|
Vaccines | 1 | 2022 | 7 | 0.210 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 95 | 0.210 |
Why?
|
Immunoglobulin E | 1 | 2022 | 11 | 0.210 |
Why?
|
Immunoglobulin A | 1 | 2022 | 14 | 0.210 |
Why?
|
Complement C1q | 1 | 2022 | 7 | 0.200 |
Why?
|
Seroconversion | 1 | 2022 | 1 | 0.200 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 5 | 0.200 |
Why?
|
Sarcopenia | 2 | 2019 | 31 | 0.200 |
Why?
|
Body Mass Index | 1 | 2024 | 427 | 0.200 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 17 | 0.200 |
Why?
|
Organoids | 1 | 2021 | 8 | 0.190 |
Why?
|
Precision Medicine | 1 | 2021 | 25 | 0.190 |
Why?
|
Follow-Up Studies | 2 | 2018 | 1738 | 0.190 |
Why?
|
Neoplasms | 2 | 2021 | 222 | 0.190 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 77 | 0.190 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 78 | 0.190 |
Why?
|
Pilot Projects | 1 | 2022 | 378 | 0.190 |
Why?
|
Bone Morphogenetic Protein 7 | 2 | 2011 | 33 | 0.190 |
Why?
|
B7-H1 Antigen | 1 | 2021 | 9 | 0.190 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 326 | 0.190 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2021 | 14 | 0.180 |
Why?
|
Observer Variation | 1 | 2021 | 93 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 723 | 0.180 |
Why?
|
Endothelin-1 | 1 | 2020 | 7 | 0.180 |
Why?
|
Mass Screening | 1 | 2022 | 166 | 0.180 |
Why?
|
Biochemistry | 1 | 2000 | 1 | 0.180 |
Why?
|
Disease Progression | 2 | 2014 | 687 | 0.180 |
Why?
|
Proteins | 1 | 2000 | 54 | 0.170 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 333 | 0.170 |
Why?
|
Weight Loss | 2 | 2019 | 120 | 0.170 |
Why?
|
Receptors, CXCR | 1 | 2019 | 1 | 0.170 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2019 | 5 | 0.170 |
Why?
|
Esophagectomy | 1 | 2019 | 21 | 0.170 |
Why?
|
Patient Selection | 1 | 2021 | 194 | 0.170 |
Why?
|
Protein Binding | 3 | 2014 | 113 | 0.170 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 44 | 0.160 |
Why?
|
RNA, Small Untranslated | 1 | 2018 | 1 | 0.160 |
Why?
|
Channelopathies | 1 | 2018 | 5 | 0.160 |
Why?
|
CA1 Region, Hippocampal | 1 | 2018 | 8 | 0.160 |
Why?
|
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2018 | 10 | 0.160 |
Why?
|
Cell Movement | 2 | 2016 | 77 | 0.150 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 12 | 0.150 |
Why?
|
Neuronal Plasticity | 1 | 2018 | 39 | 0.150 |
Why?
|
Pyramidal Cells | 1 | 2018 | 29 | 0.150 |
Why?
|
Transcriptome | 3 | 2024 | 81 | 0.150 |
Why?
|
SOS1 Protein | 1 | 2016 | 4 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2016 | 12 | 0.140 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2016 | 12 | 0.140 |
Why?
|
Kidney Tubules | 1 | 2016 | 7 | 0.140 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 160 | 0.140 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 61 | 0.130 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2016 | 42 | 0.130 |
Why?
|
Muscle, Skeletal | 1 | 2019 | 361 | 0.130 |
Why?
|
Cattle | 2 | 2013 | 135 | 0.130 |
Why?
|
Metformin | 1 | 2016 | 18 | 0.130 |
Why?
|
Hypoglycemic Agents | 1 | 2016 | 33 | 0.130 |
Why?
|
Computational Biology | 2 | 2014 | 21 | 0.130 |
Why?
|
Aggrecans | 2 | 2013 | 52 | 0.130 |
Why?
|
Cognition | 1 | 2024 | 1291 | 0.130 |
Why?
|
Mice, Transgenic | 4 | 2019 | 201 | 0.130 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2015 | 2 | 0.130 |
Why?
|
Risk Factors | 3 | 2024 | 2265 | 0.120 |
Why?
|
Repressor Proteins | 1 | 2015 | 25 | 0.120 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2011 | 49 | 0.120 |
Why?
|
Collagen Type X | 1 | 2014 | 2 | 0.120 |
Why?
|
Mice | 5 | 2020 | 1290 | 0.120 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2015 | 49 | 0.120 |
Why?
|
Minnesota | 1 | 2014 | 7 | 0.120 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 17 | 0.120 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 151 | 0.120 |
Why?
|
Microspheres | 1 | 2014 | 23 | 0.110 |
Why?
|
Cell Differentiation | 1 | 2014 | 124 | 0.110 |
Why?
|
Metabolic Syndrome | 1 | 2014 | 55 | 0.110 |
Why?
|
Choroid | 1 | 2013 | 1 | 0.110 |
Why?
|
Retinal Pigment Epithelium | 1 | 2013 | 1 | 0.110 |
Why?
|
Iris | 1 | 2013 | 2 | 0.110 |
Why?
|
Biological Assay | 1 | 2013 | 6 | 0.110 |
Why?
|
Illinois | 1 | 2014 | 231 | 0.110 |
Why?
|
Reference Values | 1 | 2014 | 184 | 0.110 |
Why?
|
src-Family Kinases | 1 | 2013 | 7 | 0.110 |
Why?
|
Collagen Type IV | 2 | 2004 | 4 | 0.110 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 237 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2014 | 210 | 0.110 |
Why?
|
In Vitro Techniques | 1 | 2013 | 171 | 0.110 |
Why?
|
Cell Proliferation | 3 | 2021 | 162 | 0.110 |
Why?
|
Postoperative Complications | 1 | 2019 | 869 | 0.110 |
Why?
|
Chondroitin Sulfates | 1 | 2013 | 5 | 0.110 |
Why?
|
Chemokine CCL3 | 1 | 2013 | 8 | 0.110 |
Why?
|
Granuloma | 1 | 2013 | 13 | 0.110 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 13 | 0.110 |
Why?
|
Amino Acid Sequence | 5 | 2015 | 133 | 0.110 |
Why?
|
Chemokine CXCL12 | 1 | 2013 | 9 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2013 | 22 | 0.110 |
Why?
|
Interleukin-10 | 1 | 2013 | 17 | 0.110 |
Why?
|
Molecular Sequence Data | 5 | 2015 | 163 | 0.110 |
Why?
|
Interleukin-1beta | 1 | 2013 | 53 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2013 | 72 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2012 | 48 | 0.100 |
Why?
|
Chronic Disease | 1 | 2014 | 419 | 0.100 |
Why?
|
Pneumonia | 1 | 2013 | 70 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2024 | 66 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 186 | 0.100 |
Why?
|
Obesity | 1 | 2014 | 279 | 0.100 |
Why?
|
Animal Experimentation | 1 | 2010 | 3 | 0.090 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 10 | 0.090 |
Why?
|
Radiography | 1 | 2013 | 616 | 0.090 |
Why?
|
Serum | 1 | 2010 | 7 | 0.090 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 13 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 162 | 0.090 |
Why?
|
Intervertebral Disc | 1 | 2010 | 127 | 0.080 |
Why?
|
Case-Control Studies | 1 | 2010 | 566 | 0.080 |
Why?
|
Mass Spectrometry | 3 | 2014 | 37 | 0.080 |
Why?
|
Sodium Dodecyl Sulfate | 1 | 2008 | 3 | 0.080 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 24 | 0.080 |
Why?
|
Phosphoproteins | 1 | 2008 | 25 | 0.080 |
Why?
|
Preoperative Care | 1 | 2009 | 122 | 0.080 |
Why?
|
Alzheimer Disease | 2 | 2018 | 2062 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 21 | 0.080 |
Why?
|
Metals | 1 | 2008 | 142 | 0.070 |
Why?
|
Signal Transduction | 3 | 2014 | 409 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 119 | 0.070 |
Why?
|
Cartilage, Articular | 1 | 2011 | 413 | 0.070 |
Why?
|
Melanoma | 2 | 2004 | 48 | 0.060 |
Why?
|
Hyaluronan Receptors | 1 | 2004 | 5 | 0.060 |
Why?
|
Metalloproteases | 1 | 2004 | 7 | 0.060 |
Why?
|
Peptide Fragments | 2 | 2004 | 74 | 0.060 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2024 | 43 | 0.060 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2015 | 33 | 0.050 |
Why?
|
Adolescent | 1 | 2009 | 2080 | 0.050 |
Why?
|
Glycosylation | 1 | 2022 | 15 | 0.050 |
Why?
|
Antibody Formation | 1 | 2022 | 18 | 0.050 |
Why?
|
Proline | 1 | 2002 | 10 | 0.050 |
Why?
|
Microsatellite Instability | 1 | 2022 | 8 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 17 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2018 | 574 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 10 | 0.050 |
Why?
|
Fluorescence | 1 | 2021 | 11 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2021 | 5 | 0.050 |
Why?
|
Genomics | 1 | 2021 | 53 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 853 | 0.050 |
Why?
|
Biological Availability | 1 | 2020 | 19 | 0.050 |
Why?
|
Vasoconstriction | 1 | 2020 | 15 | 0.050 |
Why?
|
Base Sequence | 2 | 2014 | 89 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2015 | 116 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2015 | 264 | 0.040 |
Why?
|
beta-Arrestins | 1 | 2019 | 1 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 7 | 0.040 |
Why?
|
Neuropsychological Tests | 1 | 2024 | 1223 | 0.040 |
Why?
|
Models, Biological | 1 | 2021 | 306 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 35 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 177 | 0.040 |
Why?
|
Endoplasmic Reticulum | 1 | 2018 | 18 | 0.040 |
Why?
|
Sex Factors | 1 | 2019 | 450 | 0.040 |
Why?
|
Action Potentials | 1 | 2018 | 116 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2017 | 64 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2016 | 5 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 13 | 0.030 |
Why?
|
Ubiquitination | 1 | 2016 | 10 | 0.030 |
Why?
|
A549 Cells | 1 | 2016 | 10 | 0.030 |
Why?
|
Lymphocytes | 1 | 2017 | 59 | 0.030 |
Why?
|
Fibrosis | 1 | 2016 | 26 | 0.030 |
Why?
|
Neutrophils | 1 | 2017 | 96 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 93 | 0.030 |
Why?
|
Atrophy | 1 | 2016 | 90 | 0.030 |
Why?
|
Graft Survival | 1 | 2016 | 90 | 0.030 |
Why?
|
Biopsy | 1 | 2016 | 200 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2015 | 5 | 0.030 |
Why?
|
Twist-Related Protein 1 | 1 | 2015 | 3 | 0.030 |
Why?
|
Arginine | 1 | 2015 | 16 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2015 | 29 | 0.030 |
Why?
|
Cadherins | 1 | 2015 | 34 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 69 | 0.030 |
Why?
|
Blotting, Western | 1 | 2015 | 135 | 0.030 |
Why?
|
Two-Hybrid System Techniques | 1 | 2014 | 2 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2014 | 9 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 126 | 0.030 |
Why?
|
Cyclooxygenase 2 | 1 | 2014 | 27 | 0.030 |
Why?
|
Hypertrophy | 1 | 2014 | 18 | 0.030 |
Why?
|
Binding Sites | 1 | 2014 | 65 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2014 | 27 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2015 | 80 | 0.030 |
Why?
|
Cognitive Dysfunction | 1 | 2024 | 1020 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2014 | 83 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2014 | 45 | 0.030 |
Why?
|
Wound Healing | 1 | 2015 | 149 | 0.030 |
Why?
|
DNA Methylation | 1 | 2015 | 122 | 0.030 |
Why?
|
Transcription Factors | 1 | 2014 | 159 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2013 | 3 | 0.030 |
Why?
|
Protein Kinase C beta | 1 | 2013 | 7 | 0.030 |
Why?
|
Protein Structure, Secondary | 2 | 2004 | 17 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2004 | 32 | 0.030 |
Why?
|
Ligands | 2 | 2004 | 40 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2013 | 48 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2013 | 104 | 0.030 |
Why?
|
Cell Survival | 1 | 2013 | 113 | 0.030 |
Why?
|
Phosphorylation | 1 | 2013 | 139 | 0.030 |
Why?
|
Reference Standards | 1 | 2013 | 23 | 0.030 |
Why?
|
Oligosaccharides | 1 | 2013 | 17 | 0.030 |
Why?
|
Cell Membrane | 1 | 2013 | 92 | 0.030 |
Why?
|
Support Vector Machine | 1 | 2011 | 5 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2011 | 7 | 0.020 |
Why?
|
Presenilin-1 | 1 | 2010 | 8 | 0.020 |
Why?
|
Metabolism | 1 | 2010 | 5 | 0.020 |
Why?
|
Smad Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
Gels | 1 | 2010 | 13 | 0.020 |
Why?
|
Nitriles | 1 | 2010 | 12 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2010 | 22 | 0.020 |
Why?
|
Drug Synergism | 1 | 2010 | 38 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2010 | 20 | 0.020 |
Why?
|
Triazoles | 1 | 2010 | 27 | 0.020 |
Why?
|
Bone Matrix | 1 | 2010 | 26 | 0.020 |
Why?
|
Models, Animal | 1 | 2010 | 109 | 0.020 |
Why?
|
Administration, Oral | 1 | 2010 | 100 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2010 | 57 | 0.020 |
Why?
|
Proteoglycans | 1 | 2010 | 130 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2010 | 81 | 0.020 |
Why?
|
tau Proteins | 1 | 2010 | 225 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2010 | 509 | 0.020 |
Why?
|
Caseins | 1 | 2008 | 1 | 0.020 |
Why?
|
Phosphopeptides | 1 | 2008 | 1 | 0.020 |
Why?
|
Manganese | 1 | 2008 | 3 | 0.020 |
Why?
|
Ovalbumin | 1 | 2008 | 6 | 0.020 |
Why?
|
Aging | 1 | 2018 | 1538 | 0.020 |
Why?
|
Aluminum | 1 | 2008 | 9 | 0.020 |
Why?
|
Iron | 1 | 2008 | 21 | 0.020 |
Why?
|
Serum Albumin | 1 | 2008 | 21 | 0.020 |
Why?
|
Titanium | 1 | 2008 | 172 | 0.020 |
Why?
|
DNA Primers | 1 | 2004 | 45 | 0.010 |
Why?
|
Antigens, CD | 1 | 2004 | 51 | 0.010 |
Why?
|
Stereoisomerism | 1 | 2002 | 3 | 0.010 |
Why?
|
Drug Stability | 1 | 2002 | 2 | 0.010 |
Why?
|
Biophysical Phenomena | 1 | 2002 | 29 | 0.010 |
Why?
|
Basement Membrane | 1 | 2002 | 11 | 0.010 |
Why?
|
Biophysics | 1 | 2002 | 35 | 0.010 |
Why?
|